Back to search results
Michael L. Cheng
4.8 out of 5 (77)
Michael L. Cheng

Michael L. Cheng, MD

Thoracic Medical Oncology

Thoracic Surgery and Oncology Clinic
1825 Fourth St., Sixth Floor,
San Francisco, CA 94158
(415) 885-3882
4.8 out of 5 (77)
Virtual visits available
4.8 out of 5 (77)
Virtual visits available
Thoracic Surgery and Oncology Clinic
1825 Fourth St., Sixth Floor,
San Francisco, CA 94158
(415) 885-3882

Dr. Michael L. Cheng is a medical oncologist who cares for patients with lung cancer and other tumors affecting the chest, with a particular focus on non-small cell lung cancer. He strives to provide individualized, compassionate care through precision oncology (using the genetic profile of the patient's cancer to custom-tailor treatment).

Cheng leads research centered on advancing cancer genomics and developing improved treatments for patients, including through clinical trials to evaluate new targeted therapies and immunotherapies for lung cancer. He is inspired by how research discoveries can lead to tangible benefits for patients.

Cheng earned his medical degree from the David Geffen School of Medicine at UCLA. He completed a residency in internal medicine at UCSF and a fellowship in medical oncology at Memorial Sloan Kettering Cancer Center. Before joining the UCSF faculty, he served as an assistant professor at the Dana-Farber Cancer Institute and Harvard Medical School.

Cheng is a member of the American Society of Clinical Oncology (ASCO), American Association for Cancer Research and International Association for the Study of Lung Cancer. He has received the Career Development Award from Conquer Cancer, the ASCO Foundation.

  • Board Certifications

    American Board of Internal Medicine, Medical Oncology, 2017

    American Board of Internal Medicine, Internal Medicine, 2015

  • Fellowships

    Memorial Sloan-Kettering Cancer Center, Medical Oncology & Hematology, 2018

  • Residencies

    UCSF, Internal Medicine, 2015

  • Internship

    UCSF, Internal Medicine, 2013

  • Degree

    University of California, Los Angeles David Geffen School of Medicine, 2012

  • Languages

    English

Where I see patients (1)

    My reviews

    4.8

    Overall Experience
    77 Ratings
    About our process
    Mar 26, 2025
    Dr. Cheng was extremely knowledgeable
    Feb 19, 2025
    Although he knew going into our conversation that I would not be able to participate in his study, he patiently explained everything to me and spent almost an entire hour with me. I am very grateful for his expertise in navigating my future treatment. Thank you, Dr Cheng!
    Jan 14, 2025
    Dr. Cheng was excellent in all respects. He listened to my concerns, provided excellent feedback and told me about a new test I could take if I wanted it.
    Dec 21, 2024
    Dr Cheng is extremely caring and encouraging as well as thorough in his questions regarding my treatment
    Dec 21, 2024
    Dr.Cheng is EXCELLENT
    Dec 12, 2024
    Dr. Cheng is terrific.
    Nov 09, 2024
    Dr Cheng and Leah were extremely compassionate and concerned about trouble sleeping and how irt has been affecting my level of functioning
    Aug 04, 2024
    I feelEnormously lucky to be enrolled in Dr Cheng's clinical trial. He is not only extremely knowledgeable about my type of cancer, but he is also a very caring and patient person as well
    Jul 25, 2024
    Dr Cheng is a really good listener and he addressed my concerns and gave me choices.
    Jul 25, 2024
    Simply the BEST.
    Jun 18, 2024
    We contacted Dr. Cheng, originally, for a second opinion and as we have progressed through the process he has been supportive with his advice. I really appreciate that he listens to my questions and answers them in a knowledgeable manner. His problem solving skills are top rated which is an indication of his education and experience. He definitely an asset to UCSF.
    May 19, 2024
    Again, the doctors were excellent and represented UCSF in the best possible way.

    Selected research

    See all research
    Decorative Caduceus

    A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants W...

    DFS is defined as the time from randomization to any recurrence (local, locoregional, regional or distant), occurrence of new primary NSCLC, as assessed by the investigator, or death due to any cause, whichever occurs first.

    Recruiting

    Decorative Caduceus

    Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

    Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs and clinically significant changes in laboratory values, ECGs and vital signs

    Recruiting

    Decorative Caduceus

    Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

    Evaluation of DLT of CHS-388 as a monotherapy.

    Recruiting

    Decorative Caduceus

    Study of ORIC-114 in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

    RP2D as determined by interval 3+3 dose escalation design

    Recruiting

    Contact me

    Share